{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-011808","form_type":"8-K","ticker":"APRE","cik":"0001781983","company_name":"Aprea Therapeutics, Inc.","filed_at":"2024-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.501611+00:00","generated_at":"2026-05-31T10:05:59.792049+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aprea Therapeutics reports Q2 2024 net loss of $3.5M; Phase 1 trial initiated for APR-1051","bullets":["Cash $28.7M as of June 30, 2024, up from $21.6M at Dec 31, 2023; runway extended into Q4 2025.","Net loss $3.5M ($0.58 per share) vs $3.3M ($0.87) in Q2 2023; operating loss $3.8M.","Enrollment commenced in Phase 1 ACESOT-1051 trial of APR-1051 (WEE1 inhibitor); no myelosuppression in first cohort.","ABOYA-119 Phase 1/2a trial of ATRN-119 (ATR inhibitor) continues; first five dose cohorts completed; Phase 1 readout expected 1H 2025.","Appointed Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer effective May 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-011808","json":"https://secwatch.observer/filing/0001558370-24-011808.json","markdown":"https://secwatch.observer/filing/0001558370-24-011808.md","text":"https://secwatch.observer/filing/0001558370-24-011808.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024011808/0001558370-24-011808-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781983/000155837024011808/apre-20240812x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:05:59.792049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}